Silver Book Fact

If the progression of Parkinson’s disease were slowed by 50%, there would be a 35% reduction in excess costs.

Johnson, SJ, MD Diener, A Kaltenboeck, HG Binbaum, and AD Siderowf. An Economic Model of Parkinson’s Disease: Implications for slowing progression in the United States. Mov Disord. 2013; http://www.ncbi.nlm.nih.gov/pubmed/23404374

Reference

Title
An Economic Model of Parkinson’s Disease: Implications for slowing progression in the United States
Publication
Mov Disord
Publication Date
2013
Authors
Johnson, SJ, MD Diener, A Kaltenboeck, HG Binbaum, and AD Siderowf
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • A medicine is in development that aims to prevent or reverse Alzheimer’s disease progression by using a human monoclonal antibody specifically designed to remove beta amyloid protein from the brain.  
  • Donepezil, a new Alzheimer’s medication, increased prescription costs to $1,000 per patient, however the overall health care costs decreased from $11,947 to $8,056.  
  • Use of existing or new drugs/compounds for Alzheimer’s prevention could result in a delay of onset of between 2 and 5 years.  
  • Stem Cell Therapy Study Shows Improved Motor Function in Parkinson’s
     
  • One study shows that electrical spinal cord stimulation significantly improved motor function in an animal model of Parkinson’s disease.